NCT Number: NCT02439736
EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY
The primary objective of this study is to evaluate Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of CT-positive subjects (as determined by an independent Neuroimaging Review Committee) presenting acutely with traumatic brain injury (Glasgow Coma Scale score 9-15).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- The Subject is at least 18 years of age at screening.
- The Subject has presented to a Health Care Facility (HCF) or Emergency Department (ED) with a suspected traumatically induced head injury, as a result of insult to the head from an external force.
- A Glasgow Coma Scale score of 9-15 at the time of Informed Consent.
- The subject is CT-positive for acute intracranial lesion(s) based on the local neuroradiologist's review of the subject's head CT scan.
- The CT scan and CT report used to determine eligibility must be available.
- The blood sample is collected as close to the time of head injury as possible, but no later than 12 hours.
- The Subject or their legal representative is willing to undergo the Informed Consent process prior to enrollment into this study
Exclusion criteria
- Participating in an interventional, therapeutic clinical study that may affect the results of this study (an observational study would be acceptable).
- Time of injury cannot be determined.
- Primary diagnosis of ischemic or hemorrhagic stroke.
- Venipuncture not feasible (i.e., skin integrity compromised at the venipuncture sites, blood vessel calcification (i.e., IV drug users, advanced atherosclerosis) both upper limbs missing (congenital or amputee)).
- The subject has a neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
- The subject has a history of neurosurgery within the last 30 days.
- Administration of blood transfusion after head injury and prior to the study blood draw.
- The subject is a female who is pregnant or lactating.
- The Subject is otherwise determined by the Investigator to be an unsuitable candidate for participation. If this criterion applies, a reason must be provided
Treatment and study plan
Primary outcomes
-
Correlation of assay results with presence of acute intracranial lesions
Time frame: Day 1
Sponsors and collaborators
Lead sponsor
Banyan Biomarkers, Inc
Industry
Collaborators
- U.S. Army Medical Research and Development Command
Registry information
Official study title
A PROSPECTIVE CLINICAL EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY
Acronym: ALERT-TBIx
Important dates
- Study start
- 2015
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- May 12, 2015
- Registry last updated
- Aug 8, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Estimating Brain Biomechanics Using MRI
NCT01633268
Brain Diseases, Brain Injuries
Bethesda, Maryland, United States
View Trial DetailsDiagnosis of mTBI in a Community Setting
NCT03539848
Brain Concussion, Brain Diseases
Miami, Florida, United States
View Trial DetailsVideo Review of the Frequency and Assessment of Head Impacts During the FIFA World Cup 2022TM
NCT05629169
Brain Concussion, Brain Diseases
New York, United States
View Trial DetailsSMS Messaging to Reduce Depression and Anxiety Following TBI
NCT02061553
Anxiety Disorders, Behavior
Elkins Park, Pennsylvania, United States
View Trial Details